Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naive Patients with Moderate-to-Severe Ulcerative Colitis in Japan

摘要

Background Vedolizumab (VDZ) was approved by the Japanese Ministry of Health, Labor and Welfare in 2018 for the treatment of patients with moderate-to-severe active ulcerative colitis (UC). The comparative cost-effectiveness of VDZ compared with other biologics is unknown in Japan. This information could be useful for decision makers at the time of repricing biologics for the treatment of patients with moderate-to-severe UC.